| HOME >> BIOLOGY >> TECHNOLOGY |
("Tianlong"), and Harbin First Bioengineering ("First") -- were granted the High-Technology Enterprise Certificate by the provincial government in Heilongjiang Province.
In February, the Company's wholly-owned subsidiary, Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang"), signed an exclusive distribution agreement with Shaanxi Buchang Group ("Buchang") for naftopidil dispersible tablets with an expected sales target of 100 million RMB (US $14.6 million) over five years. Jin Chuang received SFDA approval to produce and distribute naftopidil dispersible tablets, which are used to treat benign enlargement of the prostate, in 2005. Also in February, the Company announced that it had expanded the sale of its best-selling Slim Patch into South Korea and Sudan after engaging PAX-Medicare and Lai Li Investment Company as exclusive sales agents. The product is now available in 26 countries and regions.
In March, the Company announced that it received SFDA approval to manufacture two new drugs, Calcium Folinate injection, intended as an auxiliary therapy for sprue, (a disease of the small intestine), infancy- related megaloblastic anemia, and colonic and rectal cancer; and Policresulen vaginal suppositories indicated for the treatment of cervical erosion, cervicitis, and various vaginal inflammations.
2009 Outlook
"We are confident about the prospects for our business in 2009 and will continue to focus on increasing market share by both strengthening and further refining our successful sales and distribution network, building and enhancing our brand image, and making strategic acquisitions that continue to support our growth," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical, Inc.
"In 2009, we expect full year revenue to increase by 40%, or approximately
$37.0 million, to $128-$130 million, driven by growth in all of our product
sales categories. We expect th
'/>"/>
| SOURCE China Sky One Medical, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |